Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Complera in HIV-1 Controllers
NCT01777997Phase 4Completed
- Start
- Apr 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus type 1 infection (HIV-1). Primary endpoint: Change in Levels of CD8+ T-cell Activation (Percentage HLA-DR+/CD38+) at 48 weeks. Started Apr 2013; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01777997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777997.